Discussion Overview
The discussion revolves around the regulations and requirements for conducting research on diseases like ALS, particularly focusing on the use of controlled substances in animal research. Participants explore various regulatory frameworks, including the Good Laboratory Practice (GLP) regulations, DEA licensing, and animal welfare guidelines.
Discussion Character
- Technical explanation
- Debate/contested
- Exploratory
Main Points Raised
- One participant inquires about the laws regarding controlled and non-controlled substances for research involving mice, specifically concerning Schedule 2 and 3 substances.
- Another participant mentions the Good Laboratory Practice (GLP) regulations and suggests that the FDA oversees these regulations.
- It is noted that chemical supply companies sell DEA-scheduled drugs, and there may be significant administrative hurdles associated with their use.
- Concerns are raised about the complexity of regulations when dealing with research subjects, animals, or radioisotopes, and the importance of consulting professors for guidance.
- A participant shares their interest in researching ALS and discusses the potential need for a "cocktail" of drugs to treat the disease effectively.
- There is mention of the viral vector IGF-1 and its relevance to ALS research, with skepticism about non-viral delivery methods.
- Clarification is provided that both the researcher and their institution may need to be registered with the DEA to obtain controlled substances, and that all orders must be documented properly.
- Participants discuss the extensive requirements for obtaining DEA licensing, including justifying the need for substances and complying with various regulations.
- Animal research is highlighted as requiring oversight from an Institutional Review Board (IRB) and adherence to NIH guidelines, even for non-federally funded research.
- Concerns are raised about potential patent infringement if the research involves testing existing drugs, with one participant emphasizing their non-commercial motivation for research.
Areas of Agreement / Disagreement
Participants express varying levels of understanding and concern regarding the regulatory landscape for research. While some provide detailed insights into the complexities of compliance, others express uncertainty about the processes involved. No consensus is reached on the best approach to navigate these regulations.
Contextual Notes
Participants note the potential challenges and administrative burdens associated with obtaining necessary licenses and adhering to regulations, highlighting the need for thorough understanding and preparation before initiating research.